Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02004886
Recruitment Status : Completed
First Posted : December 9, 2013
Results First Posted : March 18, 2014
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus. The primary hypothesis is that MK-0893 will reduce 24-hour weighted mean glucose (WMG) significantly more than placebo.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: MK-0893 Drug: Metformin Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus
Actual Study Start Date : August 11, 2006
Actual Primary Completion Date : February 7, 2007
Actual Study Completion Date : February 7, 2007

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MK-0893 (40 mg)
MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
Drug: MK-0893
10 mg and 100 mg tablets

Drug: Placebo
Placebo tablets matching MK-0893

Drug: Placebo
Placebo tablets matching metformin

Experimental: MK-0893 (120 mg)
MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
Drug: MK-0893
10 mg and 100 mg tablets

Drug: Placebo
Placebo tablets matching MK-0893

Drug: Placebo
Placebo tablets matching metformin

Active Comparator: Metformin (2000 mg)
Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
Drug: Metformin
500 mg metformin tablets
Other Names:
  • Glucophage
  • Glucophage XR
  • Glumetza
  • Fortamet
  • Riomet

Drug: Placebo
Placebo tablets matching MK-0893

Placebo Comparator: Placebo
Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
Drug: Placebo
Placebo tablets matching MK-0893

Drug: Placebo
Placebo tablets matching metformin




Primary Outcome Measures :
  1. Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4 [ Time Frame: Baseline and Week 4 ]
    Blood samples were collected 30 minutes prior to all meals, and 15, 30, 60, 90, 120, 180 minutes post-meal, then and at midnight, 3 AM, and the next morning at 6:30 AM and 7:30 AM. A 24-hour weighted mean glucose (WMG) was determined by averaging multiple plasma glucose measurements over a 24-hour period.

  2. Number of Participants Experiencing an Adverse Event (AE) [ Time Frame: Up to 42 days ]
    An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

  3. Number of Participants Discontinuing Study Treatment Due to an AE [ Time Frame: Up to 28 days ]
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.


Secondary Outcome Measures :
  1. Change From Baseline in Fasting Plasma Glucose (FPG) [ Time Frame: Baseline and Week 4 ]
    Plasma Glucose levels were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.

  2. Change From Baseline in Fructosamine at Week 4 [ Time Frame: Baseline and Week 4 ]
    Fructosamine levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.

  3. Change From Baseline in Fasting C-peptide at Week 4 [ Time Frame: Baseline and Week 4 ]
    Fasting C-peptide levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.

  4. Change From Baseline in Fasting Insulin at Week 4 [ Time Frame: Baseline and Week 4 ]
    Fasting insulin levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.

  5. Change From Baseline in 2-hour Post-prandial Glucose Excursion at Week 4 [ Time Frame: Baseline and Week 4 ]
    2-hour post-prandial glucose excursion is the change in glucose concentration in the blood 2 hours after a meal. Change from baseline in 2-hour post-prandial glucose excursion at Week 4 is defined as Week 4 minus baseline.

  6. Change From Baseline in 3-hour Area Under the Plasma Concentration Versus Time Curve (AUC) for Glucose at Week 4 [ Time Frame: Baseline and Week 4 ]
    Blood samples collected for glucose 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour AUC for Glucose was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.

  7. Change From Baseline in 3-hour AUC for C-peptide at Week 4 [ Time Frame: Baseline and Week 4 ]
    Blood samples were collected for C-peptide 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour AUC for C-peptide was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.

  8. Change From Baseline in 3-hour Insulin Total AUC at Week 4 [ Time Frame: Baseline and Week 4 ]
    Blood samples were collected for insulin 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour Insulin Total AUC was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones [i.e., peroxisome proliferator activated receptor-gamma, PPARγ agents])
  • male or a female of non-childbearing potential. Women must be postmenopausal or premenopausal and documented surgically sterilized
  • A body mass index (BMI) that is > 20 and ≤ 40 kg/m2

Exclusion Criteria:

  • History of type 1 diabetes or assessed by the investigator as possibly having type 1 diabetes
  • History of ketoacidosis; clinically unstable or rapidly progressive diabetic retinopathy, nephropathy, neuropathy
  • Treatment for diabetes within 3 months of study participation with combination anti-hyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or pioglitazone)
  • oral corticosteroid medications within 2 weeks prior to study participation, or requires digoxin, warfarin, warfarin-like anticoagulants, theophylline, anti-dysrhythmic or anti-seizure medications, immunosuppressants, or anti-neoplastic agents, or herbal remedies
  • History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)
  • History of gastrointestinal problems or disorders or extensive bowel or gastric surgery
  • History of significant or unstable cardiovascular disease
  • History of neoplastic disease
  • History of hepatic disease
  • History of seizures, epilepsy or other neurologic disease
  • History of myelodysplastic or pre-leukemic disorders or other severe hematological disorder

Study Data/Documents: CSR Synopsis  This link exits the ClinicalTrials.gov site

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT02004886     History of Changes
Other Study ID Numbers: 0893-005
First Posted: December 9, 2013    Key Record Dates
Results First Posted: March 18, 2014
Last Update Posted: September 5, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Keywords provided by Merck Sharp & Dohme Corp.:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Therapeutic Uses
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Metformin

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Metformin
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs